Monique B. Nilsson, Ph.D.
Affiliations: | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Cell Biology, OncologyGoogle:
"Monique Nilsson"Parents
Sign in to add mentor| Isaiah J. Fidler | grad student | 2005 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
| (The role of interleukin-6 in the angiogenesis of ovarian carcinoma.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Udagawa H, Nilsson MB, Robichaux JP, et al. (2023) HER4 and EGFR activate cell signaling in NRG1 fusion-driven cancers: implications for HER2/HER3-specific vs. pan-HER targeting strategies. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer |
| Nilsson MB, Yang Y, Heeke S, et al. (2023) CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell. 41: 340-355.e6 |
| Patel SA, Nilsson MB, Yang Y, et al. (2023) IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC<. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Hong L, Lewis WE, Nilsson M, et al. (2022) Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers. 14 |
| Elamin YY, Robichaux JP, Carter BW, et al. (2022) Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 40: 754-767.e6 |
| Tsao AS, Wistuba I, Xia D, et al. (2022) Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. Jco Precision Oncology. 1: 1-10 |
| Galan-Cobo A, Stellrecht CM, Yilmaz E, et al. (2021) Enhanced vulnerability of LKB1-deficient NSCLC to disruption of ATP pools and redox homeostasis by 8-Cl-Ado. Molecular Cancer Research : McR |
| Robichaux JP, Le X, Vijayan RSK, et al. (2021) Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature |
| Gudikote JP, Cascone T, Poteete A, et al. (2021) Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. The Journal of Biological Chemistry. 101163 |
| Le X, Nilsson MB, Robichaux JP, et al. (2021) ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. Cancer Cell |